Business Wire

Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge

Share

Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics – with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology – was announced the winner of the $10,000 top prize at the 13th annual SPIE Startup Challenge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005834/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jenoptik’s Ralf Kuschnereit, far left, Swave Co-Founder and Chief Product Officer Theo Marescaux, Swave CEO Mike Noonen, and 2023 SPIE Vice President Peter de Groot. Credit: Joey Cobbs.

QART Medical, utilizing biophotonics and data for 3D analysis of sperm cells during IVF, received $5,000 for second place. PhosPrint came in third, winning $2,500, with their novel bioprinting technology that repairs in vivo human tissue during surgery. All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik.

The SPIE Startup Challenge, a pitch competition held annually by SPIE, the international society for optics and photonics, showcases new businesses, products, and technologies that address critical needs by utilizing photonics in the areas of healthcare and deep tech. This year’s finalists included innovations in medical diagnostics, medical imaging, food safety, and display technology.

“It’s a privilege just to present to a such distinguished audience,” says Swave Photonics CEO Mike Noonen. “Participating at the Startup Challenge was an award in itself, but to actually win first-place recognition, well, our team is very excited. We really want to thank the sponsors and SPIE and Photonics West for the opportunity.”

“It's very nice to get the acknowledgement,” notes QART Medical CEO and Co-Founder Alon Shalev. “The judges were very supportive, and they gave us good insights yesterday in the preparation session. I think SPIE Photonics West is a wonderful, wonderful event, and a great opportunity to see and meet people. Being acknowledged is always nice, and this feels like a real achievement.”

“It was a great experience for me,” adds Chief Technology Officer and Co-Founder of PhosPrint Ioanna Zergioti. “It was exciting for us to have the opportunity to present our startup at the SPIE Startup Challenge. It was especially great to work with the judges, and to get feedback from senior investors in the field.”

The 2023 SPIE Startup Challenge was supported by Founding Partner Jenoptik; Lead Sponsors Edmund Optics, Hamamatsu, MKS Instruments, and Thorlabs; and Supporting Sponsors NextCorps Luminate and Photonics Media. The competition judges who vetted the applicants for their business models, financial cases, and competitive advantages included Jenoptik’s Kristin Holzhey, MKS Instruments’ Marc D. Himel, Edmund Optics' Agnes Hübscher, NextCorps Luminate’s Sujatha Ramanujan, Hamamatsu Ventures’ Richard Oberreiter, and Thorlabs’ Garrett Cole.

Light-based technologies enable developments in a proliferating number of areas, from healthcare and high-speed communications to quantum computing, AR/VR/MR, and self-driving vehicles. The SPIE Startup Challenge is an annual entrepreneurial pitch competition for new businesses that utilize optics and photonics to create innovative products, applications, and technologies. Startup Challenge winners that have gone on to wider commercial success include Cellino Biotech, Double Helix Optics, PhotoniCare, C. Light Technologies, Circle Optics, and In A Blink.

About SPIE

SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye